Literature DB >> 15822042

Is desmoplasia a protective factor for survival in patients with colorectal carcinoma?

Alessandro Caporale1, Anna Rita Vestri, Eugenio Benvenuto, Mauro Mariotti, Umile Michele Cosenza, Massimo Scarpini, Andrea Giuliani, Pietro Mingazzini, Francesco Angelico.   

Abstract

BACKGROUND & AIMS: The role of desmoplasia in colorectal carcinoma progression is unclear and the presence of collagen stroma may represent a barrier against cancer diffusion and vascular invasion or a stroma to build up and support the tumor. The aim of this study was to evaluate the effect of desmoplastic response on long-term survival of patients who underwent radical resection for colorectal carcinoma.
METHODS: The study included 429 patients who underwent radical colorectal resection for cancer with a median follow-up period of 72.8 months.
RESULTS: At univariate analysis significant associations were observed between desmoplasia and histologic type, parietal infiltration, growth pattern, and staging. No associations were found between desmoplasia and the other clinical and histologic parameters. The multivariate analysis stratified for tumor stage revealed that the factor showing the most favorable influence on time to death was desmoplasia. The presence of desmoplasia was likely to decrease the failure rate to a third of the rate experienced by patients without desmoplasia. Parietal infiltration was associated with an increased risk for a shortened time to death.
CONCLUSIONS: Our results favor the view that desmoplasia is a protective factor for survival in patients with colorectal carcinoma. This finding is consistent with the hypothesis that desmoplasia may prevent cancer invasiveness by building a barrier against tumor diffusion.

Entities:  

Mesh:

Year:  2005        PMID: 15822042     DOI: 10.1016/s1542-3565(04)00674-3

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  8 in total

1.  Desmoplasia in different degrees of invasion of carcinoma ex-pleomorphic adenoma.

Authors:  Vera Cavalcanti de Araújo; Cristiane Furuse; Patricia Ramos Cury; Albina Altemani; Venâncio Avancini Ferreira Alves; Ney Soares de Araújo
Journal:  Head Neck Pathol       Date:  2007-11-27

2.  Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors.

Authors:  Kristina A Trujillo; Christopher M Heaphy; Minh Mai; Keith M Vargas; Anna C Jones; Phung Vo; Kimberly S Butler; Nancy E Joste; Marco Bisoffi; Jeffrey K Griffith
Journal:  Int J Cancer       Date:  2011-02-11       Impact factor: 7.396

3.  Stromal interactions as regulators of tumor growth and therapeutic response: A potential target for photodynamic therapy?

Authors:  Jonathan P Celli
Journal:  Isr J Chem       Date:  2012-07-24       Impact factor: 3.333

4.  Cellular localization, invasion, and turnover are differently influenced by healthy and tumor-derived extracellular matrix.

Authors:  Luca Genovese; Lidia Zawada; Antonella Tosoni; Angelita Ferri; Pietro Zerbi; Raffaele Allevi; Manuela Nebuloni; Massimo Alfano
Journal:  Tissue Eng Part A       Date:  2014-03-06       Impact factor: 3.845

5.  Colorectal cancer susceptibility loci in a population-based study: Associations with morphological parameters.

Authors:  Sam Ghazi; Susanna von Holst; Simone Picelli; Ulrik Lindforss; Albert Tenesa; Susan M Farrington; Harry Campbell; Malcolm G Dunlop; Nikos Papadogiannakis; Annika Lindblom
Journal:  Am J Pathol       Date:  2010-12       Impact factor: 4.307

6.  Desmoplasia influenced recurrence of disease and mortality in stage III colorectal cancer within five years after surgery and adjuvant therapy.

Authors:  Maddalena Zippi; Giorgio De Toma; Giovanni Minervini; Claudio Cassieri; Roberta Pica; Diodoro Colarusso; Simon Stock; Pietro Crispino
Journal:  Saudi J Gastroenterol       Date:  2017 Jan-Feb       Impact factor: 2.485

7.  Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab.

Authors:  Neel I Nissen; Stephanie Kehlet; Mogens K Boisen; Maria Liljefors; Christina Jensen; Astrid Z Johansen; Julia S Johansen; Janine T Erler; Morten Karsdal; Joachim H Mortensen; Anette Høye; Nicholas Willumsen
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 8.  CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion.

Authors:  Gurcan Gunaydin
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.